肝移植后FK 506的肾毒性问题。
The question of FK 506 nephrotoxicity after liver transplantation.
作者信息
McCauley J, Takaya S, Fung J, Tzakis A, Abu-Elmagd K, Jain A, Todo S, Starzl T E
机构信息
Department of Surgery, University of Pittsburgh School of Medicine, PA.
出版信息
Transplant Proc. 1991 Feb;23(1 Pt 2):1444-7.
Abstract
Formal studies have not been published on the nephrotoxicity of FK 506 when the drug was used from the outset. This kind of information was sought in 101 recipients of primary livers, 24 hearts, and 3 double lungs or heart-lung. Perioperative renal dysfunction was commonly seen, which appeared to be related to FK 506 doses and plasma levels, particularly when the drug was given IV. This was reversible. Late renal function has been generally satisfactory in all three cohorts of patients, and the incidence of hypertension has been low. The therapeutic index of FK 506 is a good one, as revealed by these observations in patients whose most notable achievement was a low mortality.
摘要
关于从一开始就使用FK 506时的肾毒性，尚未发表正式研究。在101例接受原发性肝脏移植、24例接受心脏移植以及3例接受双肺或心肺联合移植的受者中寻找此类信息。围手术期肾功能障碍常见，这似乎与FK 506的剂量和血浆水平有关，尤其是静脉给药时。这是可逆的。在所有三组患者中，晚期肾功能总体上令人满意，高血压发生率较低。这些观察结果表明，FK 506的治疗指数良好，这些患者最显著的成就是死亡率较低。
相似文献
1
The question of FK 506 nephrotoxicity after liver transplantation.肝移植后FK 506的肾毒性问题。
Transplant Proc. 1991 Feb;23(1 Pt 2):1444-7.
2
Liver, kidney, and thoracic organ transplantation under FK 506.在使用FK506情况下的肝脏、肾脏及胸部器官移植。
Ann Surg. 1990 Sep;212(3):295-305; discussion 306-7. doi: 10.1097/00000658-199009000-00008.
3
Use of FK 506 in pediatric patients.FK506在儿科患者中的应用。
Transplant Proc. 1991 Feb;23(1 Pt 2):924-7.
4
Nephrotoxicity after orthotopic liver transplantation in cyclosporin A and FK 506-treated patients.环孢素A和FK 506治疗的原位肝移植患者的肾毒性。
Transpl Int. 1994;7 Suppl 1:S52-7. doi: 10.1111/j.1432-2277.1994.tb01310.x.
5
Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506.FK506 作用下原位肝移植术后排斥反应的发生率及治疗情况
Transplant Proc. 1991 Feb;23(1 Pt 2):928-30.
6
Clinical features of acute reversible tacrolimus (FK 506) nephrotoxicity in kidney transplant recipients.肾移植受者急性可逆性他克莫司（FK 506）肾毒性的临床特征
Clin Transplant. 1997 Jun;11(3):237-42.
7
A clinical trial of FK 506 as primary and rescue immunosuppression in cardiac transplantation.一项关于FK 506作为心脏移植主要及挽救性免疫抑制药物的临床试验。
Transplant Proc. 1991 Feb;23(1 Pt 2):1149-52.
8
Pathologic observations in human allograft recipients treated with FK 506.接受FK 506治疗的人类同种异体移植受者的病理观察
Transplant Proc. 1990 Feb;22(1):25-34.
9
Lymphoproliferative disorders arising under immunosuppression with FK 506: initial observations in a large transplant population.在使用FK 506免疫抑制情况下出现的淋巴增生性疾病：对一大群移植受者的初步观察
Transplant Proc. 1991 Feb;23(1 Pt 2):1108-10.
10
FK 506 therapy for refractory renal allograft rejection: lessons from liver transplantation.FK506治疗难治性肾移植排斥反应：来自肝移植的经验教训。
Clin Transplant. 1996 Aug;10(4):323-32.
引用本文的文献
1
Risk factors for acute kidney injury following orthotopic liver transplantation: the impact of changes in renal function while patients await transplantation.原位肝移植术后急性肾损伤的危险因素：等待移植期间肾功能变化的影响。
BMC Nephrol. 2010 Nov 8;11:30. doi: 10.1186/1471-2369-11-30.
2
Immunosuppressive drugs in paediatric liver transplantation.儿童肝移植中的免疫抑制药物
Paediatr Drugs. 2001;3(1):43-60. doi: 10.2165/00128072-200103010-00004.
3
What have we learned about primary liver transplantation under tacrolimus immunosuppression? Long-term follow-up of the first 1000 patients.关于在他克莫司免疫抑制下进行的原位肝移植，我们了解到了什么？对首批1000例患者的长期随访。
Ann Surg. 1999 Sep;230(3):441-8; discussion 448-9. doi: 10.1097/00000658-199909000-00016.
4
Pediatric renal transplantation under tacrolimus-based immunosuppression.基于他克莫司的免疫抑制下的小儿肾移植
Transplantation. 1999 Jan 27;67(2):299-303. doi: 10.1097/00007890-199901270-00020.
5
Pregnancy after liver transplantation under tacrolimus.他克莫司治疗下的肝移植术后妊娠
Transplantation. 1997 Aug 27;64(4):559-65. doi: 10.1097/00007890-199708270-00002.
6
Clinically significant drug interactions with new immunosuppressive agents.新型免疫抑制剂的具有临床意义的药物相互作用。
Drug Saf. 1997 Apr;16(4):267-78. doi: 10.2165/00002018-199716040-00004.
7
Clinically significant drug interactions with cyclosporin. An update.环孢素的具有临床意义的药物相互作用。最新进展。
Clin Pharmacokinet. 1996 Feb;30(2):141-79. doi: 10.2165/00003088-199630020-00004.
8
9
The current status of hepatic transplantation at the University of Pittsburgh.匹兹堡大学肝脏移植的现状
Clin Transpl. 1995:145-70.
10
The Pittsburgh randomized trial of tacrolimus compared to cyclosporine for hepatic transplantation.他克莫司与环孢素用于肝移植的匹兹堡随机试验。
J Am Coll Surg. 1996 Aug;183(2):117-25.
本文引用的文献
1
Cyclosporine-associated chronic nephropathy.环孢素相关慢性肾病
N Engl J Med. 1984 Sep 13;311(11):699-705. doi: 10.1056/NEJM198409133111103.
2
Nephrotoxicity of cyclosporin A in liver and kidney transplant patients.环孢素A在肝肾移植患者中的肾毒性
Lancet. 1981 Feb 28;1(8218):470-1. doi: 10.1016/s0140-6736(81)91851-1.
3
Early and late forms of cyclosporine nephrotoxicity: studies in cardiac transplant recipients.
Am J Kidney Dis. 1987 Jan;9(1):12-22. doi: 10.1016/s0272-6386(87)80156-7.
4
Cyclosporine-associated hypertension.
Am J Med. 1988 Aug;85(2):131-3. doi: 10.1016/s0002-9343(88)80330-9.
5
Systemic hypertension associated with cyclosporine: a review.
Drug Intell Clin Pharm. 1988 Jun;22(6):443-51. doi: 10.1177/106002808802200601.
6
FK 506 for liver, kidney, and pancreas transplantation.用于肝脏、肾脏和胰腺移植的FK 506。
Lancet. 1989 Oct 28;2(8670):1000-4. doi: 10.1016/s0140-6736(89)91014-3.
7
A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase.免疫抑制剂FK506的一种受体是一种顺反肽基脯氨酰异构酶。
Nature. 1989 Oct 26;341(6244):758-60. doi: 10.1038/341758a0.
8
A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin.免疫抑制剂FK506的一种胞质结合蛋白具有肽基脯氨酰异构酶活性，但与亲环蛋白不同。
Nature. 1989 Oct 26;341(6244):755-7. doi: 10.1038/341755a0.
9
A highly sensitive method to assay FK-506 levels in plasma.一种检测血浆中FK-506水平的高灵敏度方法。
Transplant Proc. 1987 Oct;19(5 Suppl 6):23-9.
10
Acute and chronic renal failure in liver transplantation.肝移植中的急性和慢性肾衰竭
Nephron. 1990;55(2):121-8. doi: 10.1159/000185938.
Zotero 插件